Vicinia FABA in Parkinson disease patients
Phase 2
- Conditions
- Parkinson disease.Parkinson disease:Hemiparkinsonism Paralysis agitans
- Registration Number
- IRCT2013060313570N1
- Lead Sponsor
- Mashhhad university of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
age more than 40 years old and stage of the Parkinson disease 1 to 3.
Exclusion criteria: do not consenting to participate in the study; background movement disorder; allergy to Fava Bean; favism disorder; MAOI drugs Consumption and pregnancy.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Improvement in overall clinical signs. Timepoint: Before and after drug consumption. Method of measurement: Physical Examination/ UPDR Score.
- Secondary Outcome Measures
Name Time Method Serum Levodopa level. Timepoint: before and one hour after drug Consumption. Method of measurement: quantitative measurement of Serum Levodopa level by HPLC/SPECT Method.